Stockreport

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 [Yahoo! Finance]

Nuvalent, Inc. - Class A  (NUVL) 
NASDAQ:AMEX Investor Relations: nuvelinc.com/company/investor_relations.html
PDF CAMBRIDGE, Mass. Sept. 13, 2024 /PRNewswire/ -- (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinical [Read more]